Emergent BioSolutions, Inc., (EBS) a biopharmaceutical company, that, develops, manufactures, and commercializes immunobiotics in the United States, the United Kingdom, and Vietnam broke out on 2.5x its 21-day average volume. The company operates in two segments, Biodefense and Commercial. The Biodefense segment offers products for use against biological agents that are potential weapons of bioterrorism and biowarfare; and BioThrax, a vaccine for the prevention of anthrax infection.
With new military budgets approved and terrorism a constant threat we believe EBS's point and figure target of 17.50 is very feasible.